Two lenders win big in $74bn BMS Celgene merger
The US’s Bristol-Myers Squibb (BMS) has picked two banks to provide the debt portion of its $74bn acquisition of biotech firm Celgene, in one of the biggest pharmaceuticals mergers in recent years.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: